Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41)
Alectinib Shows Better Progression-Free Survival Than Crizotinib for NSCLC
This pooled analysis of Phase III trials involving 500 patients with ALK-positive NSCLC found that alectinib significantly improved progress…
Alectinib showed better progression-free survival than crizotinib in a study of 500 patients with ALK-positive lung cancer.
Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
New drug shows promise for specific type of lung cancer
This Phase 3 randomized trial of 274 patients with resected, ALK-positive stage IB to IIIB NSCLC found that ensartinib (225 mg once daily) s…
A new medication called ensartinib significantly improved the time patients lived without their lung cancer returning after surgery.